Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation Quality of life · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs observation Pain alteration · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs observation Quality of life · adults and children with sickle cell disease and an increased risk of stroke Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Pain alteration · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Life‐threatening illness · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ Hydroxyurea vs no hydroxyurea Quality of life · adults and children with sickle cell disease Hydroxyurea (hydroxycarbamide) for sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics only Need for additional IV or oral antibiotics · children and adults with pulmonary exacerbation in CF Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics vs IV antibiotics Time off work or school · children and adults with CF and an acute exacerbation Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics only Time off work or school · children and adults with pulmonary exacerbation in CF Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo Growth · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract… Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo Frequency of exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract… Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Active treatment vs observation only Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults or children with positive microbiological isolate of MRSA from a respiratory tract specimen Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral plus nebulised antibiotics vs oral antibiotics plus nebulised placebo Time until next positive MRSA isolate (from clinically relevant respiratory culture) · adults and children with cystic fibrosis and a positive microbiological isolate of MRSA from a respiratory tract… Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic… (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ laser therapy vs no laser therapy Quality of life · children and adults with SCD and PSR Laser therapy for retinopathy in sickle cell disease (2022) · Cochrane | no estimate extracted | NR | No studies |
Rilonacept vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
ImmunoGuard vs placebo Number of participants experiencing an attacka · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
ImmunoGuard vs placebo Duration of attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
ImmunoGuard vs placebo Time between attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
ImmunoGuard vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Duration of attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Time between attacks · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Anakinra vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Duration of attacks · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Time between attacks · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Canakinumab vs placebo Prevention of AA amyloidosis · people with colchicine‐resistant familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Number of participants experiencing an attack · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Time between attacks · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine single dose vs divided dose Prevention of AA amyloidosis · children with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine (oral) vs placebo Prevention of AA amyloidosis · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Colchicine (oral) vs placebo Acute‐phase response · people with familial Mediterranean fever Interventions for reducing inflammation in familial Mediterranean fever (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Quality of Life: change in CFQ‐R score · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Participant preference · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Need for extra antibiotics (days) · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Pulmonary function: absolute change FEV1 % predicted · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Change in VO2 peak during maximal exercise · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Quality of life: change in CFQ‐R score · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Change in VO2 peak during maximal exercise · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Adherence · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs underwater PEP (uPEP; also known Need for extra antibiotics (days) · children and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Quality of life · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Adherence · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise vs ACBT Need for extra antibiotics (days) · adolescents and adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Exercise plus PD&P vs PD&P only Change in VO2 peak during maximal exercise · children and young adults with cystic fibrosis Exercise versus airway clearance techniques for people with cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Statins with cholesterol supplementation vs cholesterol supplementation only Overall survival · children and adults with Smith‐Lemli‐Opitz syndrome Statins for Smith‐Lemli‐Opitz syndrome (2022) · Cochrane | no estimate extracted | NR | No studies |
Statins with cholesterol supplementation vs cholesterol supplementation only QoL · children and adults with Smith‐Lemli‐Opitz syndrome Statins for Smith‐Lemli‐Opitz syndrome (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled muscarinic antagonists vs placebo Number of exacerbations  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled muscarinic antagonists vs placebo Participant‐reported symptom score  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled muscarinic antagonists vs placebo Change from baseline in FVC (% predicted) Â · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled muscarinic antagonists vs placebo Sputum volume (mL) Â · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Change from baseline in FEV1 (% predicted) Â · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |